Germ-line mutations in BRCA2 have been linked to early-onset familial breast cancer. BRCA2 is known to play a key role in repairing double-strand breaks. Here, we describe the involvement of BRCA2 in O 6 -alkylguanine DNA alkyltransferase (AGT)-mediated repair of O 6 -methylguanine adducts. We show that BRCA2 physically associates and undergoes repairmediated degradation with AGT. In contrast, BRCA2 with a 29-amino-acid deletion in an evolutionarily conserved domain does not bind to alkylated AGT; the two proteins are not degraded; and mouse embryonic fibroblasts are specifically sensitive to alkylating agents that result in O 6 -methylguanine adducts. We show that O 6 -benzylguanine (O 6 BG), a nontoxic inhibitor of AGT, can also induce BRCA2 degradation. BRCA2 is a viable target for cancer therapy because BRCA2-deficient cells are hypersensitive to chemotherapeutic DNA-damaging agents. We show a marked effect of O 6 BG pretreatment on cell sensitivity to cisplatin. We also show the efficacy of this approach on a wide range of human tumor cell lines, which suggests that chemosensitization of tumors by targeted degradation of BRCA2 may be an important consideration when devising cancer therapeutics. [Cancer Res 2008;68(23):9973-81] 
Introduction
Breast cancer is the most frequently diagnosed cancer in women and one of the leading causes of lethality. Among the various factors responsible for the development of this cancer, a family history of the disease seems to play a major role. Women who inherit lossof-function mutations in BRCA1 or BRCA2 have up to 80% risk of developing breast cancer by the age of 70 years (1) . In addition to breast cancer, mutations in BRCA1 and BRCA2 also result in increased susceptibility to ovarian, pancreatic and prostate cancers (1) . Mutations in BRCA2 have also been implicated in Fanconi anemia, a rare autosomal recessive disease (2) .
To gain an insight into the in vivo functions of BRCA2, several knockout mouse models have been generated that revealed its role in double-strand break repair (3, 4) . Due to a critical role of Brca2 in normal embryonic development, loss-of-function mutations have resulted in lethality of mutant embryos during mid-gestation (5-7). Hypomorphic alleles of Brca2 that result in truncated BRCA2 protein have also been generated (8) (9) (10) (11) (12) (13) . Mutant mice are viable, but have several developmental defects and develop thymic lymphomas a few months after birth. Cells homozygous for these hypomorphic alleles are hypersensitive to genotoxins and show chromosomal aberrations. Conditional loss of Brca2 in mammary glands results in a higher incidence of tumors after extended latency (14) .
In a complementary approach, we are generating mutant alleles of Brca2 in mice, each bearing either a small deletion in an evolutionarily conserved region or a disease-associated missense mutation. Mutations are introduced in the Brca2 gene cloned in a bacterial artificial chromosome (BAC). Functional analysis of the mutations is done in transgenic mice lacking the endogenous Brca2 gene. The Brca2-deficient mice were generated previously by replacing exon 10 and a portion of exon 11 by gene targeting method (5) . We have rescued the mutant phenotype of the Brca2 null mice (Brca2 tm1Brd /Brca2 tm1Brd , denoted hereafter as Brca2 Ko/Ko ) by introducing into their germ line a BAC clone (RPCI 22-421A23 with a 220-kb insert) that contains the complete mouse Brca2 locus (data not shown).
BRCA2 contains eight BRC repeats located in the middle of the protein, each repeat consisting of 30 to 40 amino acids. Six of the eight repeats have been shown to interact with RAD51 (15, 16 ). An evolutionarily conserved 29-amino-acid region (amino acids 1,088-1,116) is located between repeats 1 and 2 (Fig. 1A) . Here, we describe the functional analysis of a mutant allele of Brca2 with an in-frame deletion of 87 bases in exon 11, encoding these 29 amino acids. We have generated transgenic mice expressing mutant Brca2 and found the mutant embryonic fibroblasts to be specifically sensitive to alkylating agents that result in O 6 -methylguanine adducts. BRCA2-deficient cells are known to be hypersensitive to a wide range of DNA-damaging agents due to its key role in RAD51-mediated DNA repair. The specific sensitivity of the cells expressing the mutant BRCA2 with a 29-amino-acid deletion led us to uncover the involvement of BRCA2 in repair of O 6 -methylguanine adducts. Our results validate the advantage of using hypomorphic alleles to uncover novel functions of BRCA2. We illustrate the utility and clinical relevance of this new finding.
Materials and Methods
Generation of BAC transgenic mice. An 87-bp deletion in Brca2 was generated using recombineering, and transgenic mice were generated as described previously (17) .
Genotyping mice by Southern blot analysis and genetic crosses. The Brca2 knockout mice were generated previously by replacing exon 10 and a portion of exon 11 with human Hprt minigene (5) . A single-basepair alteration in intron 11 of Brca2 was generated in the BAC to disrupt an endogenous EcoRV site, as described previously (17) . This was used to distinguish the transgene from the wild-type allele using a 1.5-kb probe specific to Brca2 exon 11 (nucleotides 5,208-6,710 of NM 009765).
Genotoxin sensitivity assays. Drug sensitivity assays were done using mouse embryonic fibroblasts (MEF) between passages 2 and 5 by trypan blue exclusion method. Cell proliferation assay was done using a Coulter counter to test sensitivity of MEFs to cisplatin in response to O 6 BG treatment. Alamar blue and clonogenic survival assays were used to screen various tumor cell lines for increased cytotoxic response to cisplatin in the presence of O 6 BG. All assays were done in triplicates and repeated at least twice. The assays are described in detail in Supplementary data.
Western blots. Total cell extracts were prepared in radioimmunoprecipitation assay (RIPA) buffer [50 mmol/L Tris-HCl (pH 8.0), 150 mmol/L NaCl, 1% NP40, 1% sodium deoxycholate, 0.1% SDS, 2 mmol/L phenylmethylsulfonyl fluoride (PMSF)] supplemented with protease inhibitors. Protein concentrations were determined by bicinchoninic acid protein assay (Pierce Biotechnology). Total cell extracts (60 Ag) were resolved on 4% to 12% denaturing gradient SDS polyacrylamide gels and transferred onto polyvinylidene difluoride membranes. Blots were probed with actin (1:5,000), O 6 -alkylguanine DNA alkyltransferase (AGT; 1:500), or BRCA2 (1:500) primary antibodies for 1 h at 25jC, followed by peroxidaseconjugated secondary antibody against mouse or rabbit IgG (1:2,000; Amersham Biosciences), and detected by the enhanced chemiluminescence-plus detection system (Amersham Pharmacia Biotech).
In vitro AGT activity. AGT activity measurements were carried out as described previously (18) . See Supplementary data for details.
Gel filtration and immunoprecipitation. Cells were extracted in RIPA buffer [50 mmol/L Tris-HCl (pH 8.0), 150 mmol/L NaCl, 1% NP40, 1% sodium deoxycholate, 0.1% SDS, 2 mmol/L PMSF] supplemented with protease inhibitors. Cell lysates (2-3 mg of total proteins) were treated with O 6 BG in the presence of 5 mmol/L NEM and 25 Amol/L MG132 at 4jC for 1 h. Untreated or O 6 BG-treated extracts were run through a Superdex 200 HR10/30 column (Pharmacia) on an AKTA FPLC system (Pharmacia) at a flow rate of 0.5 mL min
À1
. Fractions (1 mL) were collected and analyzed for the presence of AGT or BRCA2 by Western blot. To test the elution profile of free AGT, 1 Ag of recombinant human AGT in RIPA buffer was fractionated as described above. Recombinant AGT was then mixed with cell extracts (untreated and O
6
BG treated) and loaded on the column. A fraction containing both BRCA2 and AGT (Fig. 4B, fraction 7) was used for the coimmunoprecipitation experiment with anti-BRCA2 antibody (Pep3), and precipitates were probed for AGT by Western blot analysis. The fraction containing AGT but lacking BRCA2 (Fig. 4B, fraction 12 Immunofluorescence analysis. Cells plated on coverslips at 50% to 60% confluency were treated with 2 Amol/L N-methyl-N ¶-nitro-N-nitrosoguanidine (MNNG) for 1 h and allowed to recover for varying times. Paraformaldehyde-fixed cells were permeabilized with 0.1% Triton X-100 solution and blocked with 5% goat serum before staining with primary An 87-bp deletion was generated in a BAC containing a full-length BRCA2 gene that precisely deletes this 29-amino-acid region. B, scheme for genotyping mice by Southern blot analysis. The probe detects a 5.0-kb wild-type (WT ), 6.5-kb knockout (Ko ), and 9.0-kb transgenic (Tg ) fragment on Southern blot containing Eco RV (RV )-digested genomic DNA. antibody (rabbit anti-mouse AGT) in a humidifying chamber at 4jC overnight. After washing, cells were stained with the secondary antibody [Alexa Fluor 568 goat anti-rabbit IgG (H + L), 1:1,000]. After extensive washing, nuclei were counterstained with 4 ¶,6-diamidino-2-phenylindole (DAPI; 0.5 Ag/mL) and coverslips mounted onto glass slides using Vectashield mounting medium. Cells were visualized by three-dimensional confocal microscopy using a Zeiss LSM 510 microscope and a 100Â oil objective.
Results
Generation of mice with a 29-amino-acid deletion in BRCA2. We generated an in-frame deletion of 87 bases, encoding 29 amino acids encoded by codons 1,088 to 1,116 in exon 11 of Brca2 in BAC RP22-421A2 as described previously (17 Fig. 1D ). Twenty-six mutant mice were found to have tumors, including 20 that had a neoplasm as the cause of death, whereas only 12 in the control group developed any neoplasm (Supplementary Table S1A ). In addition, 13 mutant mice had multiple neoplasms, compared with only 5 in the control group. A variety of neoplasms were seen in both groups (Supplementary Table S1B ). Distinct differences in incidence of specific neoplasms between mutant and control animals were observed for hematopoietic neoplasm, including B-cell lymphoma and histiocytic sarcoma (17 in mutant compared with 5 in control mice, P = 0.0067), and pituitary adenomas (9 in mutant compared with 0 in control mice, P = 0.0027). These results suggested that the mutant mice were predisposed to tumorigenesis and the Brca2 D87 allele was not fully functional. Mutant MEFs are sensitive to SN 1 -alkylating agents. To understand the functions of BRCA2 that may be disrupted by the 29-amino-acid deletion, we generated MEFs from Brca2 D87 mutant and control (Brca2 +/+ , Brca2 +/+ ; Tg D87/+ , Brca2 Ko/+ , or Brca2
Ko/+ ; Tg D87/+ ) embryos. We observed no significant differences when proliferation of mutant and control primary MEFs were compared (data not shown). Because the 29-amino-acid region is located between the first two BRC repeats known to interact with RAD51, we first determined whether the mutation affected double-strand break repair by testing the sensitivity of MEFs to various doses of g-radiation ( Fig. 2A) . The mutant and control MEFs did not show any difference in their sensitivity to g-irradiation, suggesting that the ability of mutant BRCA2 D87 to repair double-strand break was not impaired. We also found that RAD51 foci formation in response to g-irradiation was not affected in the BRCA2 mutant cells ( Supplementary Fig. S1 ), further suggesting that there was no apparent defect in the double-strand break repair function. We then challenged the MEFs with various other genotoxins, including methyl methanesulfonate, UV-radiation, cisplatin, N-acetyl-2-acetylaminofluorene, and MNNG to determine whether any other DNA repair processes were affected. Sensitivities of the mutant and control MEFs were comparable in all cases except when treated with MNNG ( Fig. 2B ; Supplementary Fig. S2A-D) . MEFs derived from Brca2 D87 embryos were more sensitive to MNNG compared with control cells (Fig. 2B) . Although the mutant MEFs were moderately sensitive to MNNG, the sensitivity was consistently observed in independently generated primary MEFs from three different transgenic founder lines. We also confirmed the sensitivity of mutant MEFs to MNNG by a clonogenic survival assay that was done by coculturing primary MEFs with mitotically inactivated feeder cells (data not shown). MNNG is an SN 1 -type of alkylating agent that methylates guanine nucleotides, resulting in the formation of O 6 -methylguanine adducts. Surprisingly, Brca2 D87 mutant MEFs were not sensitive to other alkylating agents like methyl methanesulfonate, which produces 3-alkyladenine adduct, or N-acetyl-2-acetylaminofluorene, which modifies at the C8 position of guanine. However, Brca2 D87 mutant MEFs were also sensitive to N-methyl nitrosourea (MNU), another alkylating agent known to result in O 6 -methylguanine adducts (Supplementary Fig. S2E ). This finding suggests that the mutant cells are specifically sensitive to agents that alkylate at the O 6 position of guanine. Defect in AGT-mediated repair. O 6 -Methylguanine adducts are specifically repaired by a single protein, O 6 -alkylguanine DNA alkyltransferase (AGT), also known as O 6 -methylguanine DNA methyl transferase (MGMT; ref. 19 ). Because AGT is the only protein known to function in reversal of O 6 -methylguanine adducts, we looked at the expression of AGT in wild-type and mutant MEFs. AGT protein was detected in both mutant and control cells by Western blot analysis (Fig. 2C) and there was no difference in the expression levels. To determine whether the protein was functional, we measured its activity by an in vitro assay. The amount of 3 H-labeled methyl group that is transferred from calf thymus DNA to AGT present in the cell extract has been used to estimate AGT activity (18) . The results of this assay indicate that the AGT protein present in mutant cell extract is fully functional and has an in vitro activity comparable to the control cells (Fig. 2D) . AGT functions by transferring the alkyl group from the O 6 position of guanine in DNA to a cysteine residue within its active site (20) . AGT irreversibly binds to the alkyl group and is functionally inactivated. Subsequently, the inactive, alkylated AGT undergoes suicidal degradation via the ubiquitin proteolytic pathway (21) . We therefore looked at degradation of AGT protein by immunostaining in Brca2 D87 mutant and control MEFs at different time intervals following MNNG treatment as a measure of its in vivo activity. Control and mutant cells exhibited predominantly nuclear staining of AGT in untreated cells. In the control cells, a gradual loss of the AGT staining occurred after MNNG treatment (Fig. 3A, top) . Surprisingly, in the mutant cells, AGT did not seem to undergo degradation (Fig. 3A, bottom) . We examined 200 nuclei and found that, after 4 hours of MNNG treatment, all of the wild-type cells exhibited a marked reduction in AGT staining compared with the untreated cells, whereas only 20% of the mutant cells showed some reduction in AGT staining. After 8 hours, none of the wild-type cells showed any AGT staining, but f80% of the mutant cells still displayed strong nuclear AGT staining. We confirmed these results by Western blot analysis. In wild-type cells, but not in the mutant, degradation of AGT is detected as early as 2 hours after MNNG treatment, reaches its peak at 8 hours, and by (Fig. 3B, top) . Interestingly, we also detected a reduction in BRCA2 level as seen with AGT in wild-type cells after MNNG treatment, but no significant change was observed in mutant cells (Fig. 3B,  middle) . These results support a role for BRCA2 in the AGTmediated repair process and indicate that BRCA2 is codegraded with AGT after alkylation.
To examine whether BRCA2 was involved only in repair of DNA O 6 mG adducts or it also had a role in subsequent degradation of alkylated AGT, we tested the effect of O 6 -benzylguanine (O 6 BG), a pseudo-substrate of AGT (22) . O 6 BG alkylates AGT by transferring a benzyl group to the active site of AGT, which initiates its proteolytic degradation in a process similar to the degradation induced by the removal of an alkyl adduct from DNA (22, 23 found that the level of AGT decreased in extracts from control MEFs (Fig. 3C, top) but remained unchanged in the mutant MEF extracts, suggesting that AGT was not degraded. As seen with MNNG, BRCA2 was codegraded with AGT in response to O 6 BG treatment in wild-type cells but not in mutant cells (Fig. 3C,  middle) . These results suggest a potential role for BRCA2 in degradation of inactivated AGT, which was blocked in Brca2 D87 mutant cells.
Because BRCA2 degradation on treatment with alkylating agents has not been shown previously, we tested whether this was dependent on AGT. We used AGT-deficient MEFs and two AGTdeficient cell lines, HeLa S3 and TK6, to check BRCA2 degradation in response to O 6 BG treatment. BRCA2 was degraded in wild-type MEFs and HeLa cells on O 6 BG treatment but not in the AGTdeficient cells (Fig. 3D, middle) , indicating that BRCA2 degradation by alkylating agents depends on the presence of AGT.
AGT is associated with a BRCA2-containing complex. Because of the involvement of BRCA2 in AGT-mediated repair process, we tested by gel filtration chromatography whether the two proteins interact physically. Total proteins from wild-type and mutant MEFs were fractionated on a size exclusion column. After fractionation, each fraction was tested by Western blot analysis for the presence of BRCA2 and AGT. We found that BRCA2 eluted as a Figure 4 . BRCA2 and AGT are present in a high molecular weight complex. A, BRCA2 and AGT elute in different fractions from a size exclusion column. BRCA2 is a part of a very high molecular weight complex. In Brca2 +/+ extract, there is an increase in the amount of AGT after O 6 BG treatment, but in Brca2 D87 more AGT elutes were present in the higher fractions, and there is no increase in AGT in these fractions after alkylation. Input, endogenous BRCA2 and AGT in the cell extracts. Closed arrows, fractions in which BRCA2 and AGT coelute. B, when recombinant human AGT in buffer alone was loaded on the column, it was not present in the high-molecular weight fraction (bottom ). It coelutes with BRCA2 in a high molecular weight complex before and after O 6 BG treatment in Brca2 +/+ extract; there is an increase in the amount of AGT after O 6 BG treatment. In Brca2 D87 mutant untreated extract, more AGT elutes were present in the higher fractions compared with Brca2 +/+ untreated extract; there is no change in AGT levels in these fractions after alkylation. Input, endogenous BRCA2 and recombinant human AGT in cell extracts. Arrows, fractions in which BRCA2 and AGT coelute. C, a fraction containing BRCA2 and AGT (fraction 7 from B) from untreated (lanes 2 and 4 ) and O component of a very large molecular weight complex (>670 kDa). Interestingly, whereas the AGT levels were very low in these BRCA2-containing fractions in untreated cell extracts, the amount of AGT in these fractions increased after O 6 BG treatment (Fig. 4A , right, see fractions 7 and 8). In contrast, in the mutant extracts, a small amount of AGT coeluted with BRCA2 even in the untreated extracts and there was no significant change in the amount of AGT in the BRCA2-containing fraction on alkylation. These observations suggested that whereas interaction between wild-type BRCA2 and AGT is increased in response to alkylation, interaction between AGT and mutant BRCA2 D87 is not affected by alkylation.
To examine the elution profile of pure AGT, we fractionated human recombinant AGT protein, which has 77% amino acids sequence similarity with mouse AGT. The pure protein (24 kDa) was not present in the high molecular weight fraction and eluted in much lower fractions with a molecular weight range of 44 to 200 kDa (Fig. 4B, bottom) . When mixed with protein cell extracts, the recombinant AGT eluted in a high-molecular-weight complex with BRCA2. In addition, the amount of AGT in BRCA2-containing fractions increased after O 6 BG treatment (Fig. 4B , right, see fractions 7 and 8) compared with the fraction from untreated extracts (Fig. 4B, left) in the wild-type cells. In untreated mutant cell extracts, the level of AGT in BRCA2-containing fractions seemed to be higher when compared with the wild-type cells. The difference became even more evident when we coimmunoprecipitated AGT with BRCA2-specific antibodies from BRCA2-containing fractions. The amount of AGT pulled down with BRCA2 antibody from wild-type cells was greatly increased following O 6 BG treatment, suggesting that there was an increase in interaction between BRCA2 and alkylated AGT (Fig. 4C) . In contrast, AGT efficiently coimmunoprecipitated with BRCA2 D87 in mutant extracts even without O 6 BG treatment. Mutant BRCA2 does not bind to alkylated AGT. AGT undergoes alkylation in Brca2 D87 mutant MEFs based on its normal in vitro activity as well as on the observed change in the amount of AGT in the low molecular fraction after alkylation (Fig. 4A) . However, it is not known whether alkylated AGT can bind to mutant BRCA2
D87
. To investigate this, we performed an assay to assess the ability of wild-type and mutant BRCA2 to specifically bind the alkylated form of AGT.
3 H-radiolabeled recombinant alkylated AGT was added to cell extracts, and we subsequently performed coimmunoprecipitations. Based on the amount of radioactivity obtained after immunoprecipitation with anti-BRCA2 antibody, we estimated the amount of alkylated AGT bound to BRCA2. Alkylated AGT immunoprecipitated >6-fold more (compared with an immunoglobulin control) in wild-type cell extracts, whereas in the mutant cell extracts, the amount of 3 H-radiolabeled recombinant alkylated AGT was similar to the background level (Fig. 4D) . These results show that whereas wild-type BRCA2 is able to bind to alkylated AGT, mutant BRCA2 D87 fails to bind alkylated AGT. It is possible that the deletion of 29 amino acids causes a subtle conformational change in BRCA2 that results in altered interaction with unalkylated AGT, which may interfere with the in vivo function of AGT causing moderate sensitivity of mutant MEFs to MNNG. The altered interaction with unalkylated AGT may disrupt the interaction between BRCA2 D87 and alkylated AGT.
BRCA2 and AGT interaction in human cells. With the aim of validating the observations made in MEFs, and also to determine whether BRCA2 plays a role in AGT-mediated repair in human cells, we examined the interaction between BRCA2 and endogenous AGT in human BxPC3 cells. BxPC3 is a pancreatic adenocarcinoma cell line that expresses functional BRCA2 (24) . We performed coimmunoprecipitation with anti-AGT antibody and immunoprecipitates were probed with anti-BRCA2 antibodies. We found that BRCA2 coimmunoprecipitated with AGT in BxPC-3 cells (Fig. 5A, lane 1) . We observed an increase in the amount of BRCA2 pull-down with AGT antibodies following O 6 BG treatment in BxPC3 cells (Fig. 5A, lane 2) . These results showed that BRCA2 interacts with endogenous alkylated as well as unalkylated AGT in human cells. We then examined the repair-mediated degradation of BRCA2 and AGT in human BxPC3 cells following MNNG treatment. Consistent with the results obtained in MEFs, BRCA2 and AGT were both degraded in BXPC3 cells following MNNG treatment (Fig. 5B, left) .
AGT degradation in BRCA2-deficient cells. To examine if BRCA2 was essential for degradation of AGT, we treated the BRCA2-deficient human cancer cell line Capan-1 with MNNG. Capan-1 cells express a truncated form of BRCA2 that is only localized in the cytoplasm (25) . We found that in Capan-1 cells, AGT gradually degraded with time after MNNG treatment (Fig. 5B , right). These observations were further confirmed by using BRCA2-deficient mouse embryonic stem cells, which also showed AGT degradation after O 6 BG treatment (Fig. 5C ). These results indicated that although degradation of BRCA2 is dependent on the presence of AGT, BRCA2 is not essential for AGT degradation. It is possible that the altered interaction between AGT and BRCA2 D87 interferes with AGT degradation in BRCA2 D87 mutant MEFs.
Clinical implication of O 6 BG-mediated BRCA2 degradation. Although BRCA2 may not be essential for degradation of alkylated AGT, the fact that BRCA2 can be degraded by O 6 BG suggests that the interaction between AGT and BRCA2 can be of clinical relevance. The compromised DNA repair function of BRCA2-deficient cells is being explored as a potential target for treating such tumors (26) (27) (28) . Recent studies have shown that the targeted inhibition of poly(ADP-ribose) polymerase can kill BRCA2 mutant cells with high specificity (29, 30) . Because BRCA2-deficient cells exhibit radiation hypersensitivity, we tested the effect of O 6 BG on g-radiation sensitivity in wild-type MEFs. We found that O 6 BG rendered cells more sensitive to radiation (data not shown). However, the degree of sensitivity was not very high, which we attribute to the fact that we do not completely deplete BRCA2 by O 6 BG. We then tested the effect of O 6 BG on cisplatin sensitivity because cells expressing hypomorphic alleles of Brca2 in mice have been shown to be more sensitive to DNA interstrand cross-linking agents compared with g-irradiation (8, 10, 13) . Because cisplatin is a potent DNA cross-linking agent commonly used for chemotherapy, enhancing the sensitivity of tumor cells to cisplatin by O 6 BG will be clinically relevant (31) . To test this hypothesis, we used wild-type and mutant MEFs with and without O 6 BG pretreatment, exposed them to different doses of cisplatin, and measured the effect on cell proliferation. The wild-type cells exhibited a marked increase in sensitivity to cisplatin after O 6 BG pretreatment compared with cells that were not pretreated with O 6 BG (Fig. 6A) . As expected, Brca2 D87 mutant
MEFs showed no significant difference in their sensitivity to cisplatin in response to O 6 BG pretreatment because BRCA2
was not degraded in these cells and was able to repair the DNA damage. We next examined if O 6 BG can be used to render human tumor cells sensitive to cisplatin. Because cisplatin is commonly used to treat wide range of tumors, we tested the effect of O 6 BG on cisplatin sensitivity on various tumor cell lines including BxPC3 and those derived from lung (NCI-H460 and A549), melanoma (MDA-MB-435, SK-Mel-28, A375, UACC-62, and MALME-3E), ovary (SK-OV-3), and prostate (DU145) tumors. MDA-MB-435 was previously considered to be a breast adenocarcinoma cell line, but recently it has been reclassified as a melanoma cell line (32) . Of the 10 cell lines we tested, 8 exhibited a significant reduction in cell proliferation due to O 6 BG pretreatment ( Supplementary  Fig. S4 ). As shown in Fig. 6B Fig. S5; Fig. 6C ). Taken together, these results support our hypothesis that O 6 BG can be used to increase the sensitivity of tumor cells to chemotherapeutic agents like cisplatin. 6 BG pretreatment. MALME-3E cell line could not be tested because it failed to form colonies under conditions used in this assay.
Discussion
We have generated a small deletion in the mouse Brca2 gene and found MEFs derived from mutant embryos to be specifically sensitive to SN 1 -type alkylating agents. Since the identification of AGT more than two decades ago, it has been proposed to function alone in repairing the O 6 mG adducts caused by these agents (33) (34) (35) . We show that AGT is part of an in vivo complex containing BRCA2 and the two proteins physically interact. We also show that like AGT, BRCA2 is also degraded in the process. Our observation that AGT is degraded in BRCA2-deficient cells suggests that BRCA2 is not essential for degradation of alkylated AGT. However, BRCA2 is known to be part of a multiprotein complex including BRCA1 and BARD1 that has ubiquitin E3 ligase activity (36) . Therefore, it is possible that BRCA2 may have a regulatory or nonessential function in signaling ubiquitination and degradation of alkylated AGT.
The functional significance of the interaction between BRCA2 and AGT remains to be elucidated. We speculate that the involvement of BRCA2 in AGT-mediated repair process may provide specificity and increase the fidelity of the process. Degradation of BRCA2 may be due to the fact that it is bound to alkylated AGT and the two proteins may be targeted together as a complex for degradation. Alternatively, AGT bound to BRCA2 may not be accessible for degradation. Therefore, removal of BRCA2 may be necessary to gain access to alkylated AGT. However, in BRCA2-deficient cells, AGT is accessible and is able to undergo degradation. In contrast, we postulate that the 29-amino-acid deletion results in a conformational change in BRCA2, which alters its interaction with unalkylated AGT and interferes with its binding to alkylated AGT and degradation. Although AGT present in Brca2 D87 mutant cells has normal activity based on the in vitro activity assay, we cannot rule out the possibility that BRCA2 may play a role in the in vivo function of AGT. It may be involved in the localization of AGT to the site of DNA damage, similar to its role in localization of RAD51 to the site of a double-strand break (8) .
We show that alkylated AGT fails to undergo degradation in Brca2 D87 mutant cells. How a defect in this process results in increased tumor predisposition of mutant mice is unclear. It is possible that alkylated AGT remains bound to DNA and interferes with DNA replication, transcription, or DNA repair activities. It has also been suggested that degradation of the inactivated AGT proteins provides a signal for synthesis of additional protein (37, 38) . Therefore, although the Brca2 D87 mutant cells have functional AGT, the accumulation of alkylated form could be causing the mild sensitivity and tumor predisposition by interfering with DNA repair and synthesis of new AGT. AGT-deficient mice do not develop tumors spontaneously. However, when exposed to a very low dose of MNU, these mice develop thymic lymphomas as well as lung adenomas (39) (40) (41) . We cannot rule out the possibility that the tumor predisposition of Brca2 D87 mice is due to some other function of BRCA2 that is currently unknown, which is disrupted by the 29-amino-acid deletion. DNA alkylating agents are widely used chemotherapy drugs; however, tumor cells frequently acquire resistance to these drugs by overexpressing AGT. Depletion of AGT by its inhibitors before treatment with O 6 -alkyalting agents has been suggested to increase the efficacy of such therapy (42, 43) . In a parallel approach, depletion of BRCA2 by O 6 BG can be used to increase the sensitivity of tumor cells to DNA cross-linking agents like cisplatin. Some previous studies have shown that O 6 BG has the ability to sensitize cells to cisplatin, but the exact mechanism for this sensitivity was not clear (44) (45) (46) . One possibility was that O 6 BG and other guanine derivatives could be used to inhibit cyclin-dependent kinase-2 and enhance sensitivity of head and neck tumor cells lines to cisplatin (45, 46) . In another study, the enhancement was shown to be independent of glutathione or glutathione-S-transferase activity and nucleotide excision repair proteins (44) . We have provided a new mechanism for the effect of O 6 BG on cisplatin sensitivity and showed its efficacy on a wide range of tumor cell lines.
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